Today before the opening bell, VistaGen Therapeutics announced its reception of a Notice of Allowance from the Canadian Intellectual Property Office. The Notice of Allowance enables further expansion of VistaGen Therapeutics’ intellectual property portfolio, which consists of pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.

The notice pertains to Canadian Patent Application No. 2,487,058, which is exclusively licensed to VistaGen Therapeutics by the Icahn School of Medicine at Mt. Sinai in New York and entitled “Mesoderm and Definitive Endoderm Cell Populations”. This new development builds on VistaGen Therapeutics’ recent reception of another Notice of Allowance for Canadian Patent Application 2,684,022, both of which strengthen the company’s intellectual property portfolio relating to a number of pluripotent stem cell projects VistaGen Therapeutics has been considering pursuing in Canada.

These include: projects that involve liver safety and liver toxicity-based drug rescue; customized drug discovery assays for therapies to treat liver disease and diabetes; and exploratory nonclinical studies for potential regenerative medicine applications involving beta islet cells and other cells of the endoderm lineage.

A biotechnology company, VistaGen Therapeutics is focused on using pluripotent stem cell technology for applications in drug rescue, drug discovery, and regenerative medicine.

For more information, visit: www.VistaGen.com

Let us hear your thoughts: